NRG/RTOG 1119, “Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination with Concurrent Lapatinib in Patients with Brain Metastasis From HER2-Positive Breast Cancer: A Collaborative Study of NRG Oncology and KROG,” is closed to accrual as of 5 PM ET Thursday, September 12, 2019, because it is has reached its accrual target, as broadcast on September 10.
Reminder: Data collection and site IRB renewal for closed studies must continue until the study is terminated.
Please distribute this information to the appropriate personnel at participating affiliate/NCORP component institutions.
This message was sent to email@example.com by NRG-Broadcasts@NRGOncology.org
Four Penn Center
1600 JFK Blvd.
, Philadelphia, PA, 19103